Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Inclusion Criteria: * Patients who completed the core study CACZ885H2251. A patient is defined as completing the core study if he/she completed the study up to and including the last visit (Visit 9). * Patients who have signed a written informed consent before any trial procedure is performed. Exclusion Criteria: * Patients for whom continuation in the extension 1 is not considered appropriate by the treating physician. * Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive pregnancy test (serum or urine). * Female patients who were physiologically capable of becoming pregnant, unless they were: * Female patients whose career, lifestyle, or sexual orientation precluded intercourse with a male partner. * Female patients whose partners had been sterilized by vasectomy or other means. * Using an acceptable method of contraception with a failure rate (Pearl Index (PI)) \< 1. * Reliable contraception had to be maintained throughout the study and for 2 months after study drug discontinuation. Other protocol defined inclusion/exclusion criteria may apply